IPA Stock Overview
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
ImmunoPrecise Antibodies Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.44 |
| 52 Week High | US$6.50 |
| 52 Week Low | US$3.51 |
| Beta | 0.57 |
| 1 Month Change | -14.38% |
| 3 Month Change | -11.83% |
| 1 Year Change | -20.09% |
| 3 Year Change | 86.85% |
| 5 Year Change | 164.46% |
| Change since IPO | 2.21% |
Recent News & Updates
Shareholder Returns
| IPA | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 0.8% | 0.6% | 0.9% |
| 1Y | -20.1% | -12.5% | -10.9% |
Return vs Industry: IPA underperformed the US Life Sciences industry which returned -11.2% over the past year.
Return vs Market: IPA underperformed the US Market which returned -9.6% over the past year.
Price Volatility
| IPA volatility | |
|---|---|
| IPA Average Weekly Movement | 9.3% |
| Life Sciences Industry Average Movement | 11.6% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: IPA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: IPA's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 85 | Jennifer Bath | https://www.ipatherapeutics.com |
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its contract research organization services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.
ImmunoPrecise Antibodies Ltd. Fundamentals Summary
| IPA fundamental statistics | |
|---|---|
| Market Cap | US$110.59m |
| Earnings (TTM) | -US$18.75m |
| Revenue (TTM) | US$14.82m |
7.5x
P/S Ratio-5.9x
P/E RatioIs IPA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IPA income statement (TTM) | |
|---|---|
| Revenue | CA$19.93m |
| Cost of Revenue | CA$8.98m |
| Gross Profit | CA$10.95m |
| Other Expenses | CA$36.15m |
| Earnings | -CA$25.20m |
Last Reported Earnings
Oct 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.01 |
| Gross Margin | 54.95% |
| Net Profit Margin | -126.47% |
| Debt/Equity Ratio | 0% |
How did IPA perform over the long term?
See historical performance and comparison